Iterum Therapeutics

OverviewSuggest Edit

Iterum Therapeutics is a clinical-stage pharmaceutical company which aims to treat serious infections resulting from multi-drug resistant bacteria. It is engaged in developing differentiated anti-infectives. The Company offers an oral and intravenous antibiotic for the treatment of Gram-negative multi-drug resistant infections.
TypePrivate
Founded2015
HQDublin, IE
Websiteiterumtx.com

Latest Updates

Employees (est.) (Nov 2021)23
Cybersecurity ratingAMore
Discover new suppliers and conduct deeper comparison analysis with Craft for EnterpriseLearn more
Banner background

Key People/Management at Iterum Therapeutics

Corey N. Fishman

Corey N. Fishman

CEO & Director
Mark Chin

Mark Chin

Director
Brenton K. Ahrens

Brenton K. Ahrens

Interim Chairman
Michael Dunne

Michael Dunne

Director
Judith M. Matthews

Judith M. Matthews

CFO
Tom Loughman

Tom Loughman

Senior Vice President, Technical Operations
Show more

Iterum Therapeutics Office Locations

Iterum Therapeutics has offices in Dublin, Chicago and Old Saybrook
Dublin, IE (HQ)
4th Floor, Block 2, Harcourt Centre, Harcourt Street, Dublin 2
Chicago, IL, US
200 South Wacker Drive, 200 S Wacker Dr #2550
Old Saybrook, CT, US
20 Research Pkwy
Show all (3)

Iterum Therapeutics Financials and Metrics

Summary Metrics

Founding Date

2015

Iterum Therapeutics total Funding

$105 m

Iterum Therapeutics latest funding size

$65 m

Time since last funding

5 years ago

Iterum Therapeutics investors

Iterum Therapeutics's latest funding round in May 2017 was reported to be $65 m. In total, Iterum Therapeutics has raised $105 m
Show all financial metrics

Iterum Therapeutics Cybersecurity Score

Cybersecurity ratingPremium dataset

A

94/100

SecurityScorecard logo

Iterum Therapeutics Online and Social Media Presence

Embed Graph

Iterum Therapeutics News and Updates

Iterum Therapeutics Reports Third Quarter 2021 Financial Results and Provides Business Update

--Type B meeting with FDA requested to affirm design for additional Phase 3 trial needed for resubmission of NDA for Oral Sulopenem-- --Cash Runway into 2024--    --Iterum to host conference call today at 8:30am ET--

Iterum Therapeutics to Provide Business Update and Report Third Quarter 2021 Financial Results on November 12, 2021

DUBLIN, Ireland and CHICAGO, Nov. 05, 2021 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the Company), a clinical-stage pharmaceutical company focused on developing next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community …

Thinking about buying stock in Farmmi, Iterum Therapeutics, EQT Corp, SoFi Technologies, or Regis Corp?

NEW YORK, Sept. 29, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for FAMI, ITRM, EQT, SOFI, and RGS. To see how InvestorsObserver's proprietary scoring system rates these stocks, view the InvestorsObserver's PriceWatch Alert by selecting the corresponding link....

Iterum Therapeutics Provides Update from FDA Type A Meeting Regarding Oral Sulopenem

DUBLIN, Ireland and CHICAGO, Sept. 28, 2021 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the Company), a clinical-stage pharmaceutical company focused on developing next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community…

Iterum Therapeutics to Present Data at IDWeek 2021

DUBLIN, Ireland and CHICAGO, Sept. 28, 2021 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the “Company”), a clinical-stage pharmaceutical company focused on developing next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both communi…

ITRM UPCOMING DEADLINE: Investors with Substantial Losses Have Opportunity to Lead the Iterum Therapeutics plc Class Action Lawsuit

SAN DIEGO, Sept. 25, 2021 /PRNewswire/ -- Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Iterum Therapeutics plc (NASDAQ: ITRM) securities between November 30, 2020 and July 23, 2021, inclusive ("Class Period") have until October 4, 2021 to seek appointment as...
Show more

Iterum Therapeutics Blogs

Iterum Therapeutics Appoints Beth P. Hecht to Board of Directors

Patrick Heron to leave the Board DUBLIN, Ireland and CHICAGO, March 16, 2021 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the “Company” or “Iterum”), a clinical-stage pharmaceutical company focused on developing next generation oral and IV antibiotics to treat infections caused by …

Iterum Therapeutics Announces Pricing of $17.5 Million Upsized Public Offering

DUBLIN, Ireland and CHICAGO, Oct. 23, 2020 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM), a clinical-stage pharmaceutical company focused on developing next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hospital s…

UPDATE -- Iterum Therapeutics to Present Data from Phase 3 Trials in Uncomplicated and Complicated Urinary Tract Infections at IDWeek 2020

Data presentations to cover both SURE-1 and SURE-2 urinary tract infection studies DUBLIN, Ireland and CHICAGO, Oct. 19, 2020 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the “Company”), a clinical-stage pharmaceutical company focused on developing next generation oral and IV antib…

Iterum Therapeutics to Present Data from Phase 3 Trials in Uncomplicated and Complicated Urinary Tract Infections at IDWeek 2020

Data presentations to cover both SURE-1 and SURE-2 urinary tract infection studies DUBLIN, Ireland and CHICAGO, Oct. 19, 2020 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the “Company”), a clinical-stage pharmaceutical company focused on developing next generation oral and IV antibiot…

Iterum Therapeutics to Present at the 22nd Annual H.C. Wainwright Global Investment Conference

DUBLIN, Ireland and CHICAGO, Sept. 08, 2020 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the “Company”), a clinical-stage pharmaceutical company focused on developing next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both communi…

Iterum Therapeutics Announces Revised Results of Rights Offering

DUBLIN, Ireland and CHICAGO, Sept. 02, 2020 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the “Company”), a clinical-stage pharmaceutical company focused on developing next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both communi…
Show more

Iterum Therapeutics Frequently Asked Questions

  • When was Iterum Therapeutics founded?

    Iterum Therapeutics was founded in 2015.

  • Who are Iterum Therapeutics key executives?

    Iterum Therapeutics's key executives are Corey N. Fishman, Mark Chin and Brenton K. Ahrens.

  • How many employees does Iterum Therapeutics have?

    Iterum Therapeutics has 23 employees.

  • Who are Iterum Therapeutics competitors?

    Competitors of Iterum Therapeutics include MSD KK, ReCept Pharmacy and Boiron.

  • Where is Iterum Therapeutics headquarters?

    Iterum Therapeutics headquarters is located at 4th Floor, Block 2, Harcourt Centre, Harcourt Street, Dublin 2, Dublin.

  • Where are Iterum Therapeutics offices?

    Iterum Therapeutics has offices in Dublin, Chicago and Old Saybrook.

  • How many offices does Iterum Therapeutics have?

    Iterum Therapeutics has 3 offices.